The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development
Author:
Affiliation:
1. Tempo Pharmaceuticals, Cambridge, Massachusetts 02142, USA
2. Taligen Therapeutics, Cambridge, Massachusetts 02142, USA
Publisher
SAGE Publications
Subject
Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine
Link
http://journals.sagepub.com/doi/pdf/10.1177/0192623309332997
Reference29 articles.
1. Safety evaluation to support first-in-man investigations II: Toxicology studies
2. Leukocyte Adhesion Deficiencies: Molecular Basis, Clinical Findings, and Therapeutic Options
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study;BMC Medicine;2023-07-05
2. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312);Clinical and Translational Science;2021-12-08
3. Pharmacokinetic characterization of drugs and new product development;Biopharmaceutics and Pharmacokinetics Considerations;2021
4. Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia;Saudi Pharmaceutical Journal;2020-10
5. Comparing the Effect of Acupressure and Foot Reflexology on Anxiety and Depression in Hemodialysis Patients: A Clinical Trial;Medical - Surgical Nursing Journal;2020-01-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3